Communiqué from Extraordinary General Meeting
February 02, 2009 06:23 ET
|
Oasmia Pharmaceutical AB
2009-02-02
PRESS RELEASE
At...
Oasmias läkemedelskandidat Paclical® visar lovande resultat hos svårt cancersjuka patienter
January 27, 2009 07:45 ET
|
Oasmia Pharmaceutical AB
I en första studie med Paclical® i människa fastställdes den maximalt
tolererbara dosen hos produktkandidaten till 250 mg/m2. Totalt behandlades 34
patienter med långt framskriden cancersjukdom....
Oasmia Pharmaceutical's drug candidate Paclical® shows promising results in patients with severe cancer
January 27, 2009 07:45 ET
|
Oasmia Pharmaceutical AB
In an initial study with Paclical® in humans carried out by Oasmia
Pharmaceutical AB, Uppsala, Sweden, the maximum tolerable dose of the candidate
was set to 250 mg/m2. In total 34 patients with...
Solid scientific evidence for Oasmia product candidate Paccal® Vet
January 21, 2009 04:41 ET
|
Oasmia Pharmaceutical AB
PRESS RELEASE
Two clinical studies have now been completed in client owned dogs with Oasmia's
product candidate Paccal® Vet. The first was a Phase I/II study on different
types of cancers and...
Starka vetenskapliga bevis för Oasmias produktkandidat Paccal® Vet
January 21, 2009 04:41 ET
|
Oasmia Pharmaceutical AB
PRESSMEDDELANDE
Två kliniska studier på hund har nu slutförts med Oasmias produktkandidat
Paccal® Vet. I den första...
FDA grants Oasmia Pharmaceutical Expedited Review Status (ERS) for Paclical® Vet
January 14, 2009 05:43 ET
|
Oasmia Pharmaceutical AB
2009-01-14
PRESS RELEASE
Oasmia has been...
FDA beviljar Oasmia Pharmaceutical prioritet (Expedited Review-status) för
January 14, 2009 05:43 ET
|
Oasmia Pharmaceutical AB
2009-01-14
PRESSMEDDELANDE
...
OASMIA: OASMIA PHARMACEUTICAL AB (PUBL.) KALLELSE TILL EXTRA BOLAGSSTÄMMA
January 12, 2009 06:00 ET
|
Oasmia Pharmaceutical AB
(NGM:OASM A)
Aktieägarna i Oasmia Pharmaceutical AB (publ.) org. nr 556332-6676 kallas
härmed till extra bolagsstämma fredagen den 30 januari 2009 kl 15.00, plan 7,
Vallongatan 1, 752 28 Uppsala....
OASMIA: OASMIA PHARMACEUTICAL AB DELÅRSRAPPORT FÖR PERIODEN 1 MAJ - 31 OKTOBER 2008
December 10, 2008 06:00 ET
|
Oasmia Pharmaceutical AB
(NGM: OASM A)
KORT OM PERIODEN maj - oktober 2008
• Koncernens nettoomsättning uppgick till 59 785 tkr (21 506 tkr)
• Rörelseresultatet var 16 993 tkr (-16 453 tkr)
• Resultatet efter skatt...
OASMIA: PRESS RELEASE
December 01, 2008 06:00 ET
|
Oasmia Pharmaceutical AB
Oasmia appoints E. Öhman J:or Fondkommission AB as market maker and financial
advisor as well as forwards the publication of the interim report
Oasmia Pharmaceutical AB (publ) has appointed E....